SCM LifeScience Co

SCM LifeScience Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is -2,618.77 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 81.22 % — a change of -3,324.26% (lower).

Cash Conversion

-2,618.77 %

YoY

-3,324.26%

Last updated:

Cash Conversion Rate (OCF/Net Income) of SCM LifeScience Co is 2025 -2,618.77 % . Cash Conversion Rate (OCF/Net Income) of SCM LifeScience Co was 2024 81.22 % . It decreases by -3,324.26% lower compared to the previous year.

The SCM LifeScience Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
16.37 KRW
Jan 1, 2019
19.79 KRW
Jan 1, 2020
113.05 KRW
Jan 1, 2021
59.52 KRW
Jan 1, 2022
48.72 KRW
Jan 1, 2023
50.65 KRW
Jan 1, 2024
81.22 KRW
Jan 1, 2025
-2,618.77 KRW
The SCM LifeScience Co Cash Conversion history
YEARCash ConversionYoY
-2,618.77 %-3,324.26%
81.22 %+60.36%
50.65 %+3.95%
48.72 %-18.15%
59.52 %-47.35%
113.05 %+471.20%
19.79 %+20.93%
16.37 %-94.28%
286.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Cash Conversion Rate (OCF/Net Income) of SCM LifeScience Co is -2,618.77 % in 2025.

Cash Conversion Rate (OCF/Net Income) of SCM LifeScience Co changed from 81.22 % to -2,618.77 %, representing a -3,324.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s SCM LifeScience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co